| Pharmaceutical Information |
| Drug Name |
Cerivastatin |
| Drug ID |
BADD_D00415 |
| Description |
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal Rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market. |
| Indications and Usage |
Used as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate. |
| Marketing Status |
approved; withdrawn |
| ATC Code |
C10AA06 |
| DrugBank ID |
DB00439
|
| KEGG ID |
D07661
|
| MeSH ID |
C086276
|
| PubChem ID |
446156
|
| TTD Drug ID |
D03KIA
|
| NDC Product Code |
Not Available |
| UNII |
AM91H2KS67
|
| Synonyms |
cerivastatin | Kazak | cerivastatin sodium | 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, monosodium salt, (S-(R*,S*-(E)))- | 7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyrid-3-yl)-3,5-dihydroxy-6-heptenoate sodium salt | rivastatin | Certa | Bay w 6228 | Baycol | Lipobay |
|
| Chemical Information |
| Molecular Formula |
C26H34FNO5 |
| CAS Registry Number |
145599-86-6 |
| SMILES |
CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)O)O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
